KRP297

• CAT Number: I007530
• CAS Number: 213252-19-8
• Molecular Formula: C20H17F3N2O4S
• Molecular Weight: 438.42
• Purity: ≥95%
• Synonyms: KRP297; KRP-297; KRP 297; L 410198; L410198; MK-0767; MK-767.;5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide
• Target: Vitamin D Related/Nuclear Receptor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
• InChI: InChI=1S/C20H17F3N2O4S/c1-29-15-7-4-12(9-16-18(27)25-19(28)30-16)8-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)
• InChIKey: NFFXEUUOMTXWCX-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)CC2C(=O)NC(=O)S2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F

KRP297(CAT: I007530), also known as MK-0767 or MK-767, is a dual agonist of peroxisome proliferator-activated receptors (PPARα and PPARγ), being studied for its potential in treating type 2 diabetes and dyslipidemia. In preclinical studies using ob/ob mice, KRP297 demonstrated significant efficacy by dose-dependently reducing plasma glucose and insulin levels (0.3 to 10 mg/kg). It also improved insulin-stimulated 2-deoxyglucose (2DG) uptake in soleus muscle, addressing impaired glucose transport. KRP297 holds promise for not only ameliorating hyperglycemia but also preventing the progression of diabetic syndromes by improving skeletal muscle glucose metabolism. This makes it a valuable tool in metabolic disease research and therapeutic development.